Abstract:Objective To investigate the effects of early treatment of montelukast on the airway inflammation and remodeling in murine asthma model.Methods Twenty-four mice were divided into 3 groups(8 in each group) including group A[ovalbumin(OVA) sensitized/challenged mice],group B(saline sensitized/challenged mice),group C(OVA sensitized/challenged mice treated with montelukast in the early phase).Mice were sensitized on day1 and day14 by OVA and challenged from days 24 to 41 by OVA repeatedly to establish a murine model of asthma characterized by airway inflammation and airway remodeling.Monterlukast(6 mg/kg) were given from the day before OVA challenge in group C.The differential counts of inflammatory cells in bronchoaveolar lavage fluids(BALF),peripheral blood(PB) as well as eosinophils(EOS) count in bone marrow(BM) were calculated.Airway inflammation indices,EOS count,amount of collagen deposition around the bronchus,area of airway smooth muscle,the degree of mucus secretion in the lumens and depth of airway smooth muscle(ASM) in bronchus of different grade were studied by HE,PAS and Masson′s staining.The supernatant collected from BALF,PB,and BM were assayed for IL-5.The BALF were also assayed for INF-γ(levels).Results In repeatedly OVA-challenged mice (group A),EOS counts in BALF,PB and BM [(45.09±4.08) ×10~4/mL,(2.41±0.31)×10~5/mL,(1.51±0.18)×10~6/femur] were increased significantly when compared with group B[(0.08±0.03)×10~4/mL,(0.62±0.09)×10~4/mL,(0.63±0.09)×10~6/femur,all P<0.01],respectively.The IL-5 levels in BALF and PB in group A increased significantly compared with group B [BALF:((57.86±)2.72) pg/mL vs (18.68±2.46) pg/mL,P<0.01;PB:(18.76±0.84) pg/mL vs(12.11±0.51) pg/mL,P<0.01] while IFN-γ in BALF decreased significantly [(36.55±1.71) pg/mL vs(64.53±5.72) pg/mL,P<0.01].EOS counts around bronchus were increased in group A [(912.12±65.97)/mm~2] when compared with group B[(8.79±2.61)/mm~2,P<0.01].Goblet cells hyperplasia [(51.12±3.50)% vs((1.92±)0.67)%,P<0.01 ]and mucus hypersecretion [score:(3.48±0.12) vs(0.17±0.08),P<0.01],airway smooth muscle hypertrophy [(25.99±0.89)μm~2/μm vs(13.06±0.60) μm~2/μm,(P<)0.01],enhanced collagen deposition of reticular basement membrane(RBM) [(29.69±2.02) μm~2/μm vs(5.56±0.35)μm~2/μm,P<0.01] were more significant in group A than those in group B.Treated with Montelukast early resulted in decreased EOS counts [(6.25±0.79)×10~4/mL in BALF,(0.71±0.11)×10~5/mL in PB and(0.77±0.10)×10~6/femur in BM],declined IL-5 levels [(25.96±1.79)pg/mL in BALF,(13.14±0.55) pg/mL in serum] and increased IFN-γ levels [(52.70±2.15)pg/mL in BALF].Montelukast also attenuated the remodeling procedure in the airway described above.Conclusions Prolonged allergen exposure could induce airway structural changes characteristic of excessive collagen deposition.Montelukast,an anti-(inflammatory) agent,has inhibitory activity on airway remodeling.

Montelukast, a Leukotriene Receptor Antagonist, Modulates Lung CysLT1

Montelukast modulates lung CysLT1 receptor expression and eosinophilic inflammation in asthmatic mice

Montelukast as a successful treatment for eosinophilic cystitis in an asthmatic woman patient.

Effects of Montelukast on Muc5ac Expression in Lung of Asthmatic Mice

Study on Cysteinyl Leukotriene Receptor Antagonist Depressing Acute Asthma Airway Inflammation

Changes of Eosinophils in Bronchoalveolar Lavage Fluid of Asthma in Children and the Modulation Effect of Montelukast

Effect of montelukast on the apoptosis of eosinophil in bronchoalveloar lavage fluid

Research Progress of Cysteinyl Leukotriene Antagonist Montelukast

Effects of montelukast on airway inflammation and remodeling in murine model of asthma

Cys-leukotrienes mediate lung dysfunction but not histopathologies in an IL-5/Eotaxin-2 double transgenic mouse model of severe asthma

The contribution of the WNT pathway to the therapeutic effects of montelukast in experimental murine airway inflammation induced by ovalbumin and lipopolysaccharide

Montelukast reduces eosinophilic inflammation by inhibiting both epithelial cell cytokine secretion (GM-CSF, IL-6, IL-8) and eosinophil survival

Effect of montelukast on the secretion of mucus protein in human bronchial epithelial cells

Effects of Ozone Repeated Short Exposures on the Airway/lung Inflammation, Airway Hyperresponsiveness and Mucus Production in a Mouse Model of Ovalbumin-Induced Asthma.

Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist

Cough, asthma, and cysteinyl-leukotrienes

The Efficacy of Montelukast on the Airway Hyperresponsiveness in Children with Asthmatic Bron-chitis

The effects of neutralizing anti-murine interleukin-17A monoclonal antibody on ozone-induced inflammation and glucocorticoids insensitivity in a murine model of asthma

Small-Airway Dysfunction is Involved in the Pathogenesis of Asthma: Evidence from Two Mouse Models.

Cysteinyl Leukotriene Receptor Antagonism by Montelukast to Treat Visual Deficits

The Progress in the Application of Leukotrienes Modulators in the Treatment of Asthma